Blagden Sarah

Dr Sarah Blagden graduated from Charing Cross and Westminster Medical School in 1994, and later started specialist training in medical oncology at Addenbrooke Hospital, Cambridge, and as a CRUK Clinical PhD Fellow at Cambridge University. Prior to coming to Imperial College in 2006, and to LOC, she was a clinical fellow within the Cancer Drug Development (Phase I) unit at the Royal Marsden Hospital where she completed her specialist training. Since her appointment as Senior Lecturer at Imperial College in 2006, she has specialised in ovarian cancer. She is Oncology Trials Lead for Ovarian Cancer Action, a charity centred at Imperial College, who fund some of her research. She has published a number of articles and book chapters on ovarian cancer and has a special interest in survivorship. She is the UK representative on the GCIG Survivorship Committee, and a member of the HCA/LOC Supportive & Palliative Care Executive Board. In addition, she is director of the Hammersmith Early Cancer Trials (Phase I) Unit. Sarah’s laboratory research focuses on genes that are dysregulated in cancer and her research team is based in the Institute of Reproductive and Developmental Biology (IRDB), Hammersmith Campus.